Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
Am Heart J
; 233: 1-4, 2021 03.
Article
em En
| MEDLINE
| ID: mdl-33245905
ABSTRACT
Recognizing that body surface area (BSA) is a commonly used metric to inform medication dosing across fields of medicine, it is possible that patients with heart failure with reduced ejection fraction (HFrEF) with higher BSA may be more likely to tolerate higher doses of GDMT. Using the HF-ACTION trial, we examined (1) the relationship between BSA and achievement of target dosing of evidence-based beta-blocker and angiotensin-converting enzyme inhibitor (ACEI) therapy, and (2) the associations and interactions between target dosing, clinical outcomes, and BSA.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Superfície Corporal
/
Inibidores da Enzima Conversora de Angiotensina
/
Antagonistas Adrenérgicos beta
/
Insuficiência Cardíaca
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am Heart J
Ano de publicação:
2021
Tipo de documento:
Article